A new imaging method for DLBCL using iron contrast
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new imaging technique using a special iron-based contrast agent (ferumoxytol) to see if it can better spot immune cells called macrophages in your lymphoma. If you have DLBCL that has come back or not responded to treatment, this study may help doctors get a clearer picture of your disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma called DLBCL that has come back or not responded to treatment.
- A recent scan (CT, MRI, PET, or ultrasound) must show that you still have areas of lymphoma.
- You must be able to understand the study and give written permission to take part.
- You cannot be pregnant or breastfeeding.
- You cannot have anemia or kidney problems.
- You cannot have a known allergy to the iron-based contrast agent (ferumoxytol) or any IV iron products.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the biology of certain lymphomas to better understand why some people respond well to treatment and others don't. It involves giving a small additional blood or tissue sample to help researchers find genetic clues that could improve future care.
This study looks at how certain blood tests (like CRP, albumin, and their ratios) might help predict how well treatment works for newly diagnosed DLBCL. If you are getting R-CHOP, this trial could help doctors better understand your response to therapy.
This trial tests a combination of radiation, immune-boosting drugs, and a targeted antibody for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma (a type of brain lymphoma). The goal is to see if this approach is safe and effective.
This trial tests whether two special MRI contrast medicines—gadolinium and ferumoxytol—can better diagnose problems in the brain or central nervous system. It may help doctors identify what’s causing symptoms or abnormal brain findings.
This early (Phase 1) study tests how a special scan works in people with relapsed or hard-to-treat leukemia types. The scan uses a tracer called 18F FLT, and the study looks to see if it can be done safely (without sedation) and how it relates to treatment.
This trial tests a new combination of drugs (tafasitamab + lenalidomide + gemcitabine + oxaliplatin) against a standard combination (rituximab + gemcitabine + oxaliplatin) for people with DLBCL that has returned or stopped responding to prior therapy. The goal is to see if the new combination works better.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.